AMR SURVEILLANCE NETWORKS

PUBLIC-PRIVATE PARTNERSHIPS FOR THE DEVELOPMENT AND STRENGTHENING OF INFORMATION SYSTEMS.

BIOMÉRIEUX







Gabriel PEDONE - Global Health Partnerships Director

MEDELLIN - July 12th, 2023

ACKNOWLEDGEMENTS TO DR. PILAR RAMON & MARCELO GALAS FOR THE INVITATION AND THE OPPORTUNITY TO PRESENT ON HOW A PRIVATE COMPANY CAN CONTRIBUTE TO GLOBAL EFFORTS TO COMBAT ANTIMICROBIAL - RESISTANCE (AMR) -

> PRESENTATION MADE ON BEHALF OF LATAM BIOMERIEUX TEAM



AGENDA



• Ecology of the local healthcare institution (lab/hospital)



AMR Surveillance Networks (public health officials)


ECOLOGY OF THE LOCAL HEALTHCARE INSTITUTION (HOSPITAL)








FROM CLINICIAN DEMANDS TO DATA SURVEILLANCE



A SCALABLE SOLUTION: FROM LOCAL HEALTHCARE INSTITUTIONS (HOSPITAL) TO PUBLIC HEALTH OFFICIALS



¿QUÉ ES R·E·A·L?

ACCOUNTS ON A

Information management system for infectious disease management, which integrates with the hospital environment and facilitates timely clinical decisions, through optimized workflows and superior connectivity.

WHAT MIDDLEWARE OFFER ? RELEVANT INFORMATION & MICROBIOLOGICAL STATISTICS FOR CLINICAL DECISION MAKING


- Lab Manager dashboard: Allows to display the main KPIs (Key Performance Indicators) to deliver the current view of the lab activity ("what happen on my lab"),
- Blood culture dashboards:
 - Analysis: positivity rate analysis,
 - · Efficiency: insight into efficiency of blood culture workflow including mean load time and instrument capacity,
 - · Bottle volume: blood volume assessment,
 - Contaminants: contamination rate analysis,

• ID & AST dashboards:

- · Analysis: organisms found in the lab and their associated susceptibility profile,
- · Organism trend: trending of organism occurrence,
- MDRO phenotype: trending of resistance patterns,
- Cumulative antibiogram: epidemiology / AMS
 - Cumulative antibiogram as the view of the ecosystem of the institution in order to improve empiric antibiotherapy (probabilist antibiotherapy),
- Lab Performance dashboards:
 - Lab efficiency: time to results and lab efficiency analysis,
 - · Gram staining: insight as to the Gram staining step of the microbiology lab workflow,
 - Vitek MS Spotting analysis: efficiency and quality of the VITEK MS spotting activity.



" I NEED AMR SURVEILLANCE ON VRE (VANCOMYCIN RESISTANT ENTEROCOCCUS)



Deliver a global view of organisms found in the lab and their associated susceptibility profile.



The data used are demo data and are not meant to give any clinical considerations

" IS THE SUDDEN INCREASE IN ACINETOBACTER BAUMANNII CASES LINKED TO HAI? "

Prepare Data manager	Analyze Narrate Sheet Storytelling	CLARION™ Lab Analytics 5.0 ∨			_
Image: Construction of the second s	nii X Institution Name X Service Name Institution B Service 5	×	00	☐ Bookmarks ∨ 📮 Sheets ∨ < >	🗶 Eo
CLARION [®] Organism	ns Trend				
★	Analysi	is <u>Trend</u>	MDRO		$\stackrel{\circ}{\simeq}$
<i>р</i> —ъ,					
Date Collected	Organisms occurrence (Top 15)	(<u>3M</u>) (<u>6M</u>) ((IT Deduplic	cate 🧲
L, = Date Determined	40			Or	ganism
ੂਊ L∓ Room	30			32	Aci.baum
Room ∎m≣	20 -		19 22	23	
Specimen Type Group					
Invasive Non-invasive	10 5	4	4	6	
	0 1 1 1 Feb 2019 May 2019 Feb 2023	1 1 1 Mar 2021 Apr 2021 May 2021	Jun 2021 Jul 2021 Aug 2021 S	Sep 2021 Oct 2021 Nov 2021	
Organism	Organisms occurrence	- ·····	Organisms occurrence per location		
Gram Gram	120 119 100 -	Organism	80		ganism
	80	Acinetobacter baumannii	60		Acinetoba baumanni
Antibiotic Family	60		40		
Antibiotic	40		26		
	20			2	
MD RO Yes No	e		ROOM ROOM ROOM ROOM	⁵⁰	

BIOMÉRIEUX

The data used are demo data and are not meant to give any clinical considerations

CUMULATIVE ANTIBIOGRAM

		Prepare Data manager	~	Analyze Sheet		Narrate Storytelling	CLARION™	Lab Analytics 5.0 🗸					
E	3	Antibiotic 13 of 59	×	Organism 8 of 836	×						okmarks 🗸 🗔 Sheets 🗸	<	💉 Edit sh
CLARIC	DN [™] lytics	Cumulat	ive An	tibiogram									
													පි
j L⊒ Da	ate Collect	ed		I I as R	I as S		3	м (6М) (<u>1Y</u> <u>2Y</u>	All		团 Deduplic	cate
L , ⊒ Da	ate Determ	ined	Ant	ibiotic suscepti	bility (num	ber of isolat	tes)						
			Org	anism Q	Antibiotic	Family Q	Antibiotic Q						
↔ MB					AMINOGLYCOSIDES		BETA-LACTAMS						
					Am	nikacin	Gentamicin	Ampicillin	Cefepime	Cefoxitin	Ceftazidime	Er	tapenem
Spec	imen Type	Group	Enterol	bacter cloacae	88.2% (3,974)	1	78.3% (3,978)	1.6% (576)	51.9% (1,337)	0.2% (3,972)	49.4% (3,973)	74.5% (3,973	3)
Inva	asive	Non-invasive	Entero	coccus faecalis	-		-	99.1% (5,458)	-	-	-	-	
			Entero	coccus faecium	-		-	19.4% (1,887)	-	-	-	-	
Organism			ichia coli	97.4% (41,096	9)	94.1% (41,106)	46.2% (41,074)	81.1% (4,531)	92.9% (41,066)	91.7% (41,082)	99.0% (41,039)		
		Klebsie	ella oxytoca	91.7% (2,022)		86.0% (2,024)	0.2% (2,024)	67.5% (425)	88.9% (2,023)	83.3% (2,024)	92.1% (2,024	4)	
t Gran	m @) (Gram	Klebsie	ella pneumoniae	89.9% (9,197)		79.3% (9,198)	0.1% (9,191)	56.7% (1,903)	85.7% (9,193)	66.7% (9,198)	94.1% (9,192	2)
			Proteu	s mirabilis	98.5% (4,289)	l.	86.1% (4,291)	55.8% (4,287)	96.5% (230)	97.5% (4,286)	98.4% (4,287)	99.1% (4,285	5)
Antik	biotic Fami	lu.	Pseudo	omonas aeruginosa	88.4% (8,009)	1	86.7% (8,014)	-	81.6% (7,917)	-	82.2% (7,999)	-	
Antib	Jone Tam	iy											
Antib	biotic												
E L⊒ Re	esistance p	henot											
	es) (No											
		NO							_				



BIOMÉRIEUX

The data used are demo data and are not meant to give any clinical considerations

AMR SURVEILLANCE NETWORKS





CLARION™ AMR SURVEILLANCE NETWORKS - DEFINITION

AMR surveillance is a critical tool for clinicians and public health officials to improve AMS strategy.


An important cornerstone in the control of AMR is a well-designed **<u>quantitative</u>** system for the surveillance of spread and temporal trends in AMR from local healthcare institution (hospital) to a larger area (large cities, provinces, countries).

This AMR surveillance tool must also be **<u>qualitative</u>** and so based on <u>**standardized**</u> routine data from microbiological laboratories (result <u>deduplication</u>, data <u>mapping</u>, <u>breakpoints</u>...).

A **high frequency** (e.g. monthly based) surveillance supports the possibility of detection of resistance evolution that may be more accurate by merging the AMR surveillance data from microbiological laboratories of a large area.


CLARION™ AMR SURVEILLANCE NETWORKS - MOCKUP

Temporal and geographical trends in AMR from local healthcare institution (hospital) to a larger area (large cities, provinces, countries).




BIOMÉRIEUX

This mockup is not contractual and does not constitute any commitment. The data that are present into the demonstration platform are demonstration data and are not meant to give any clinical considerations, only to demonstrate the capabilities of the tool.




FOR INTERNAL USE ONLY

OVERVIEW OF CURRENT SURVEILLANCE DATA WORKLOW/ MALAWI EXAMPLE



REAL TIME AMR SURVEILLANCE DEPLOYING BIOMERIEUX SOLUTIONS







« MAKE I.T REAL »

PIONEERING DIAGNOSTICS